Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -57.72 Million EUR | 23.57% |
| 2022 | -104.72 Million EUR | -141.49% |
| 2021 | -46.86 Million EUR | -3.4% |
| 2020 | -45.32 Million EUR | -548.31% |
| 2019 | 9.71 Million EUR | -29.77% |
| 2018 | 13.96 Million EUR | 95.78% |
| 2017 | 4.59 Million EUR | 909.8% |
| 2016 | -1.49 Million EUR | 26.77% |
| 2015 | -1.24 Million EUR | 88.95% |
| 2014 | -11.21 Million EUR | 12.56% |
| 2013 | -13.35 Million EUR | -69.41% |
| 2012 | -7.68 Million EUR | -635.15% |
| 2011 | -1.03 Million EUR | 82.23% |
| 2010 | -6.07 Million EUR | -46.73% |
| 2009 | -4.7 Million EUR | -116.79% |
| 2008 | -1.82 Million EUR | 39.63% |
| 2007 | -2.51 Million EUR | -662.01% |
| 2006 | 605 Thousand EUR | -42.26% |
| 2005 | 998 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -21.79 Million EUR | -133.04% |
| 2024 Q1 | -22.35 Million EUR | 369.83% |
| 2023 Q4 | -24.44 Million EUR | -10.78% |
| 2023 Q2 | -18.06 Million EUR | -10.7% |
| 2023 Q3 | -22.06 Million EUR | -22.13% |
| 2023 FY | - EUR | 23.57% |
| 2023 Q1 | -16.32 Million EUR | 70.93% |
| 2022 Q2 | -142.61 Million EUR | -674.7% |
| 2022 Q1 | -18.4 Million EUR | -110.44% |
| 2022 FY | - EUR | -141.49% |
| 2022 Q4 | -56.14 Million EUR | -160.18% |
| 2022 Q3 | 93.29 Million EUR | 165.42% |
| 2021 Q1 | -23.46 Million EUR | -7596.17% |
| 2021 Q2 | -53.83 Million EUR | -129.45% |
| 2021 FY | - EUR | -3.4% |
| 2021 Q4 | 176.33 Million EUR | 210.07% |
| 2021 Q3 | -160.2 Million EUR | -197.58% |
| 2020 Q2 | -21.22 Million EUR | -976.9% |
| 2020 Q4 | 313 Thousand EUR | 101.19% |
| 2020 FY | - EUR | -548.31% |
| 2020 Q1 | 2.42 Million EUR | -36.67% |
| 2020 Q3 | -26.27 Million EUR | -23.82% |
| 2019 Q2 | -5.65 Million EUR | -159.84% |
| 2019 Q4 | 3.82 Million EUR | 38.64% |
| 2019 FY | - EUR | -29.77% |
| 2019 Q1 | 9.44 Million EUR | 17.15% |
| 2019 Q3 | 2.75 Million EUR | 148.76% |
| 2018 Q1 | 4.9 Million EUR | 196.0% |
| 2018 FY | - EUR | 95.78% |
| 2018 Q4 | 8.06 Million EUR | 1983.2% |
| 2018 Q3 | 387 Thousand EUR | -70.3% |
| 2018 Q2 | 1.3 Million EUR | -73.41% |
| 2017 FY | - EUR | 909.8% |
| 2017 Q4 | -5.1 Million EUR | -235.53% |
| 2017 Q2 | 4.21 Million EUR | 24.94% |
| 2017 Q3 | 3.76 Million EUR | -10.61% |
| 2017 Q1 | 3.37 Million EUR | 869.86% |
| 2016 Q1 | 41 Thousand EUR | -99.49% |
| 2016 FY | - EUR | 26.77% |
| 2016 Q4 | -438 Thousand EUR | 63.44% |
| 2016 Q3 | -1.19 Million EUR | -131.8% |
| 2016 Q2 | 3.76 Million EUR | 9087.8% |
| 2015 Q2 | -5.28 Million EUR | -404.58% |
| 2015 Q1 | -1.04 Million EUR | 77.6% |
| 2015 FY | - EUR | 88.95% |
| 2015 Q4 | 8.02 Million EUR | 3648.13% |
| 2015 Q3 | 214 Thousand EUR | 104.05% |
| 2014 Q4 | -4.67 Million EUR | -507.14% |
| 2014 Q3 | 1.14 Million EUR | 255.98% |
| 2014 Q1 | -3 Million EUR | -42.25% |
| 2014 FY | - EUR | 12.56% |
| 2014 Q2 | -736 Thousand EUR | 75.49% |
| 2013 Q2 | -3.28 Million EUR | -116.55% |
| 2013 Q3 | -6.16 Million EUR | -87.64% |
| 2013 Q1 | -1.51 Million EUR | -5.35% |
| 2013 FY | - EUR | -69.41% |
| 2013 Q4 | -2.11 Million EUR | 65.75% |
| 2012 Q4 | -1.44 Million EUR | -4.2% |
| 2012 Q3 | -1.38 Million EUR | 0.0% |
| 2012 FY | - EUR | -635.15% |
| 2011 FY | - EUR | 82.23% |
| 2010 FY | - EUR | -46.73% |
| 2009 FY | - EUR | -116.79% |
| 2008 FY | - EUR | 39.63% |
| 2007 FY | - EUR | -662.01% |
| 2006 FY | - EUR | -42.26% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 18.745% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -873.535% |
| SQZ Biotechnologies Company | -64.14 Million USD | 10.011% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -232.297% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 161.379% |
| Mesoblast Limited | -62.38 Million USD | 7.485% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3657.693% |
| Genus plc | 73.7 Million USD | 178.318% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -773.022% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1527.292% |
| Marizyme, Inc. | -34.28 Million USD | -68.371% |
| ContraFect Corporation | -64.99 Million USD | 11.199% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -558.003% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1175.243% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4017.54% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -2082.686% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2383.841% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -11041.868% |
| Accustem Sciences Inc. | -3.74 Million USD | -1440.671% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -19.684% |
| EV Biologics, Inc. | -1.26 Million USD | -4455.169% |
| Q BioMed Inc. | -617.62 Thousand USD | -9245.431% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1715.901% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9027.048% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2426.604% |
| Biomind Labs Inc. | -1.03 Million USD | -5479.243% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 684.388% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -706.002% |
| Skye Bioscience, Inc. | -13.54 Million USD | -326.055% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3780.566% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -230780.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1385.974% |
| IMV Inc. | -35.52 Million USD | -62.484% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -263.711% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2206.989% |
| GB Sciences, Inc. | -1.41 Million USD | -3965.118% |
| Alpha Cognition Inc. | -9.7 Million USD | -494.708% |
| HST Global, Inc. | -5303.00 USD | -1088340.505% |
| CSL Limited | 4.78 Billion USD | 101.205% |
| Halberd Corporation | -74.27 Thousand USD | -77607.024% |
| Enzolytics Inc. | -2.12 Million USD | -2620.038% |
| Resverlogix Corp. | -11.74 Million USD | -391.569% |
| Affymax, Inc. | -14.29 Million USD | -303.778% |
| SYBLEU INC | -141.57 Thousand USD | -40671.062% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1784.417% |
| argenx SE | -216.02 Million USD | 73.281% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -4.303% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 4842.81% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -3750.809% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 15335.823% |
| AVAX Technologies, Inc. | -6.11 Million USD | -844.272% |
| Zenith Capital Corp. | -8.6 Million USD | -570.695% |
| Genscript Biotech Corporation | -248.71 Million USD | 76.793% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -331224.264% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2259.326% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -32690.916% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -45.622% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1895.626% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -5416.519% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 858517.609% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -3198.288% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2904.824% |
| BioStem Technologies, Inc. | -7.55 Million USD | -664.134% |
| ONE Bio Corp. | 13.61 Million USD | 524.005% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -31774.006% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2706.028% |
| Agentix Corp. | -1.37 Million USD | -4107.745% |
| LadRx Corporation | 412.28 Thousand USD | 14100.092% |
| Cell Source, Inc. | -4.27 Million USD | -1250.957% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -15618.055% |
| Regen BioPharma, Inc. | 1.46 Million USD | 4037.362% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -6060.421% |
| NovAccess Global Inc. | -1.03 Million USD | -5477.906% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 751.923% |
| Itoco Inc. | -1.86 Million USD | -2988.291% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -15104.678% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -5072.043% |
| Kadimastem Ltd | -2.62 Million USD | -2099.376% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -24035.48% |
| CytoDyn Inc. | -18.02 Million USD | -220.151% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -72936.48% |
| Mobile Lads Corp. | -2.24 Million USD | -2475.453% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -471892.804% |
| Qrons Inc. | -40.08 Thousand USD | -143908.383% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -11784.417% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 11043.57% |
| Rebus Holdings, Inc. | -951 Thousand USD | -5969.401% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5334.977% |
| International Stem Cell Corporation | 202 Thousand USD | 28674.257% |
| Bioxytran, Inc. | -3.82 Million USD | -1410.937% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -109550.456% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2244.5% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -60.919% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -128166.667% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -2008.108% |
| Neutra Corp. | -181.24 Thousand USD | -31746.044% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -186.324% |
| PureTech Health plc | -11.62 Million USD | -396.431% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -186.343% |
| IXICO plc | -707 Thousand USD | -8064.074% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -651.074% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -19.389% |
| CSL Limited | 4.73 Billion USD | 101.22% |
| Cellectis S.A. | -92.63 Million USD | 37.692% |